Ty Atteberry Joins GT Medical Technologies as Sales VP

GT Medical Technologies Inc., has hired Ty Atteberry as vice president of Sales.
 
“We are excited to welcome Mr. Atteberry to our leadership team as we expand access to GammaTile in the United States,” GT Medical Technologies President Shane Brown said. “Ty’s commercial expertise, strategic mindset, and process orientation will help us further accelerate the adoption and utilization of GammaTile across the country, as we partner with clinicians to reach patients with newly diagnosed malignant and recurrent operable brain tumors.”
 
Atteberry has 27 years of experience spanning the neurology, neurosurgery, and oncology fields. He has led sales, marketing, business development, market access, and client services to drive revenue growth for medical device companies such as Medtronic, Abbott, Monteris Medical, and IMRIS. Notably, he has been recognized for assembling high-performing individuals and building teams that surpass sales objectives.
 
Beyond his professional achievements Atteberry brings a personal dedication to this cause by being a cancer survivor himself. Speaking about his new role, he shared, “I’m proud to join a company committed to advancing the care of patients with brain tumors. It is rare to see an organization of our size so dedicated to continue investing in developing robust, randomized, clinical outcome data. Becoming part of a leadership team that focuses on patients, clinicians and science every day is deeply rewarding. I look forward to broadening the adoption of GammaTile Therapy to many more patients and hospitals across the country to serve our corporate purpose.”
 
GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue. GammaTiles are bioresorbable collagen embedded with radioactive seeds, Cesium 131. Since GammaTile Therapy received U.S. Food and Drug Administration (FDA) clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed tumors, more than 1,000 patients have benefitted from its design that targets any remaining cancer cells after a tumor is surgically removed.
 
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This treatment eliminates the need for one to six weeks of daily external beam radiation therapy,allowing patients to go about their daily lives without the need for additional trips to the hospital or clinic for ongoing treatment. Since its full U.S. market release in March 2020,GammaTile has been offered in more than 95 hospitals, with more centers being added each month.